ID   A2780/cDDP
AC   CVCL_Y180
DR   cancercelllines; CVCL_Y180
DR   CGH-DB; 9110-4
DR   Wikidata; Q54606601
RX   PubMed=14973057;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 05-10-23; Version: 11
//
RX   PubMed=14973057; DOI=10.1158/0008-5472.CAN-3263-2;
RA   Yasui K., Mihara S., Zhao C., Okamoto H., Saito-Ohara F., Tomida A.,
RA   Funato T., Yokomizo A., Naito S., Imoto I., Tsuruo T., Inazawa J.;
RT   "Alteration in copy numbers of genes as a mechanism for acquired drug
RT   resistance.";
RL   Cancer Res. 64:1403-1410(2004).
//